Praxis Precision Medicines

OverviewSuggest Edit

Praxis Precision Medicines is a company that develops therapies intended for patients and families affected by complex and debilitating brain disorders. Its therapy targets genes that control the imbalance in neuronal signaling that underlies CNS disorders, enabling patients to get treatment for psychiatric disorders, movement disorders, and rare pediatric epilepsies.
TypePublic
Founded2015
HQCambridge, MA, US
Websitepraxismedicines.com

Latest Updates

Employees (est.) (Sept 2020)50
Share Price (May 2021)$25.9
Cybersecurity ratingAMore

Key People/Management at Praxis Precision Medicines

Marcio Souza

Marcio Souza

Chief Executive Officer
Stuart Chaffee

Stuart Chaffee

Chief Business Officer, Chief Financial Officer
Bernard Ravina

Bernard Ravina

Chief Medical Officer
Steven Petrou

Steven Petrou

Co-Founder & Chief Scientific Officer
Karl Hansen

Karl Hansen

Senior Vice President of CMC
Kiran Reddy

Kiran Reddy

Co-Founder and Member of the Board
Show more

Praxis Precision Medicines Office Locations

Praxis Precision Medicines has an office in Cambridge
Cambridge, MA, US (HQ)
1 Broadway
Show all (1)

Praxis Precision Medicines Financials and Metrics

Praxis Precision Medicines Revenue

USD

Net income (FY, 2020)

(61.8m)

EBIT (FY, 2020)

(62.0m)

Market capitalization (11-May-2021)

998.5m

Closing stock price (11-May-2021)

25.9

Cash (31-Dec-2020)

296.6m

EV

703.4m
Praxis Precision Medicines's current market capitalization is $998.5 m.
Annual
USDFY, 2018FY, 2019FY, 2020

General and administrative expense

3.9m6.2m17.0m

R&D expense

18.8m29.6m45.0m

Operating expense total

22.7m35.8m62.0m

EBIT

(22.7m)(35.8m)(62.0m)
Half Year
USDH1, 2019H1, 2020

General and administrative expense

3.1m4.1m

R&D expense

14.5m15.9m

Operating expense total

17.6m20.0m

EBIT

(17.6m)(20.0m)
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

18.0m44.8m296.6m

Prepaid Expenses

5.7m

Current Assets

19.1m45.5m302.3m

PP&E

103.0k128.0k82.0k
Quarterly
USDQ2, 2020

Cash

19.7m

Current Assets

20.4m

PP&E

108.0k

Total Assets

22.7m
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

(26.5m)(35.5m)(61.8m)

Depreciation and Amortization

1.0k37.0k50.0k

Accounts Payable

1.7m(837.0k)960.0k

Cash From Operating Activities

(20.7m)(33.4m)(52.6m)
Quarterly
USDQ2, 2019Q2, 2020Q3, 2020

Net Income

(17.5m)(19.9m)(36.1m)

Depreciation and Amortization

17.0k20.0k30.0k

Accounts Payable

553.0k912.0k544.0k

Cash From Operating Activities

(15.8m)(18.5m)(32.4m)
USDFY, 2018

Financial Leverage

-0.5 x
Show all financial metrics

Praxis Precision Medicines Operating Metrics

Q2, 2020

Discovery Stage Products

1

Pre-Clinical Phase Products

1

Phase I Trials Products

1

Phase II Trials Products

2
Show all operating metrics

Praxis Precision Medicines Acquisitions / Subsidiaries

Company NameDateDeal Size
Praxis Precision Medicines Australia PTY LTD
Praxis Security Corporation

Praxis Precision Medicines Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

SecurityScorecard logo

Praxis Precision Medicines Online and Social Media Presence

Embed Graph

Praxis Precision Medicines News and Updates

Praxis Precision Medicines to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update on Wednesday, March 17, 2021

CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today anno…

Praxis Precision Medicines Announces CFO Transition

CAMBRIDGE, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, today announced t…

Praxis Precision Medicines to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, today announced t…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX

NEW YORK, Nov. 11, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Praxis Precision Medicines, Inc. ("Praxis" or the "Company") (NASDAQ: PRAX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext....

Praxis Precision Medicines upsizes IPO by 35%, now looks to raise up to $180 million

Praxis Precision Medicines Inc. has increased the number of shares it plans to sell in its initial public offering by 35%, as the Massachusetts-based biopharmaceutical company developing treatments for central nervous system disorders now looks to raise up to $180.0 million. The company disclosed t…
Show more

Praxis Precision Medicines Frequently Asked Questions

  • When was Praxis Precision Medicines founded?

    Praxis Precision Medicines was founded in 2015.

  • Who are Praxis Precision Medicines key executives?

    Praxis Precision Medicines's key executives are Marcio Souza, Stuart Chaffee and Bernard Ravina.

  • How many employees does Praxis Precision Medicines have?

    Praxis Precision Medicines has 50 employees.

  • Who are Praxis Precision Medicines competitors?

    Competitors of Praxis Precision Medicines include XBiotech, Confo Therapeutics and Sigilon.

  • Where is Praxis Precision Medicines headquarters?

    Praxis Precision Medicines headquarters is located at 1 Broadway, Cambridge.

  • Where are Praxis Precision Medicines offices?

    Praxis Precision Medicines has an office in Cambridge.

  • How many offices does Praxis Precision Medicines have?

    Praxis Precision Medicines has 1 office.